Mochida Debuts Japanese Teriparatide Biosimilar
Biosimilar Of Eli Lilly’s Forteo Hits Japanese Market
Mochida has launched the first Japanese teriparatide biosimilar rival to Eli Lilly’s blockbuster osteoporosis drug Forteo. The company is hoping for big sales for the injectable in the country where the government is aiming to rein in healthcare costs for its rapidly ageing population.
You may also be interested in...
Hungary’s Gedeon Richter is continuing efforts to bring multiple biosimilars to market, while reaping the benefits of the biosimilar to Eli Lilly’s Forsteo (teriparatide) in the EU and Japan. Management discussed Richter’s achievements on the company’s first-half earnings call, while also commenting on how markets have reacted to the COVID-19 pandemic.
Pfenex believes it and commercial partner Alvogen could enjoy an extended period as the only direct competitor to Eli Lilly’s Forteo teriparatide reference brand in the US.
Richter’s Terrosa biosimilar to Lilly’s Forsteo teriparatide brand made a modest start in Europe. But the Hungarian group still posted nine-month Pharmaceutical sales growth of 8.1%.